Menu
Takes about two minutes.
Ozempic is Novo Nordisk's original semaglutide injection for type 2 diabetes. It was approved by the CDSCO in September 2025 and launched in India on 12 December 2025 [3]. It is the diabetes-indicated semaglutide, not the obesity one, and it carries trial evidence for reducing cardiovascular and kidney events alongside lowering HbA1c. This page explains that evidence, the risks, the cost and who it suits. Whether it is right for you is a decision for a doctor, not a checkout page.
What Ozempic is
Ozempic and Wegovy contain the same molecule, semaglutide, made by the same company. The difference is the licensed indication and the dose range.
Ozempic is approved for type 2 diabetes, as an adjunct to diet and exercise, and is supplied at 0.25 mg, 0.5 mg and 1 mg weekly [3]. Wegovy is approved for chronic weight management and goes up to 2.4 mg. People often lose weight on Ozempic, because that is what semaglutide does, but weight loss is not what it is licensed for in India.
Ozempic received CDSCO approval in September 2025 and was launched by Novo Nordisk on 12 December 2025 [3]. It is a Schedule H, prescription-only medicine. A Karespot doctor can assess whether it is clinically appropriate for you in a ₹599 online consultation.
Ozempic belongs to the incretin family of medicines. Here is what it actually does in the body, without the jargon.
Ozempic contains semaglutide, a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, one of the incretin hormones your gut releases after eating, closely enough to act like the real thing but last about a week instead of minutes.
It prompts insulin release only when blood sugar is high and suppresses glucagon at the same time. Because the effect is glucose-dependent, the risk of hypoglycaemia from semaglutide alone is low.
Your stomach empties more gradually and you feel full sooner, which flattens post-meal glucose spikes and usually produces weight reduction alongside the HbA1c improvement.
Ozempic is Novo Nordisk's own brand and the reference product every Indian generic is measured against for bioequivalence.
Ozempic works by restoring a hormone signal your gut already produces. Here is the chain, from the first bite to a lower HbA1c.
Food reaching your small intestine triggers the release of GLP-1, a hormone your body already makes after every meal. In type 2 diabetes this incretin response is blunted. Natural GLP-1 breaks down within minutes; the semaglutide in Ozempic sustains the same signal for about a week.
What happens
Semaglutide improves insulin secretion when glucose is high and suppresses glucagon, the hormone that raises blood sugar. Because both effects are glucose-dependent, they ease off as your blood sugar normalises, which is why hypoglycaemia risk from the medicine alone is low.
What happens
Your stomach empties more gradually, so sugar enters the blood as a trickle rather than a spike. GLP-1 also acts on the appetite centres of the brain, so intake tends to fall, which is why weight reduction usually accompanies the glycaemic benefit.
What happens
These benefits are established for semaglutide at the doses Ozempic supplies. Which of them apply to you depends on your diagnosis and your cardiovascular and kidney status. Numbered references link to the sources at the end of this page.
Powerful glycaemic control in adults with type 2 diabetes, as an adjunct to diet and exercise [5].
In SUSTAIN-6, semaglutide cut major adverse cardiovascular events by about 26% over roughly two years in adults with type 2 diabetes at high cardiovascular risk [1].
In the FLOW trial, semaglutide 1 mg reduced major kidney events by about 24% in adults with type 2 diabetes and chronic kidney disease [2].
Weight loss is a well-established effect of semaglutide, and most people see it alongside the improvement in blood sugar.
These are outcome trials of semaglutide at the doses Ozempic supplies, published in the New England Journal of Medicine. Each stat links to its source. They describe what the medicine achieved in the populations studied, alongside standard care. Averages are not promises: results vary with your starting point, dose, adherence and the rest of your treatment.
lower risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes at high cardiovascular risk.
SUSTAIN-6 · NEJM 2016 [1]lower risk of major kidney events on semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease, across 3,533 participants.
FLOW · NEJM 2024 [2]Ozempic launched in India by Novo Nordisk, following CDSCO approval in September 2025.
Reuters · December 2025 [3]Medical information verified by Dr. Prakrati Garg · Medical Content Author, Karespot · 29 August 2026
Whether Ozempic suits you depends on your glycaemic control, your cardiovascular and kidney risk, and the rest of your regimen. Meeting the criteria below is the starting point of a medical assessment, not a guarantee of a prescription.
The licensed indication: improving glycaemic control as an adjunct to diet and exercise, typically where existing therapy has not reached target.
The outcome data is strongest in adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease [1][2].
Your doctor screens your medical history for contraindications (including pregnancy, type 1 diabetes, and a personal or family history of medullary thyroid carcinoma or MEN 2), reviews your existing medication for interaction and hypoglycaemia risk, and checks for a history of diabetic retinopathy before any prescription decision. If Ozempic isn't right for you, we will tell you, and point you to what is. Meet our medical team.
Your next step
One call with an NMC-registered Internal Medicine doctor tells you whether semaglutide fits your situation, and which brand and dose make sense in your case.
These are the gastrointestinal side-effect rates reported for semaglutide at the 1 mg dose in the pooled SUSTAIN safety data, shown against placebo, because context matters [5]. They describe the molecule rather than any one brand, so they apply to Ozempic and to every other semaglutide product at this dose. Most effects were mild to moderate, occurred mainly during dose escalation, and settled with time.
Rates are approximate, drawn from pooled semaglutide safety data in the prescribing information [5]; confirm against your pack insert. · Manufacturer information
Rare but serious risks (pancreatitis, gallbladder disease and severe allergic reactions) are screened for against your personal and family history before any prescription. One finding deserves specific mention: in SUSTAIN-6, diabetic retinopathy complications were more frequent on semaglutide than on placebo, thought to relate to the speed of glucose lowering in people with pre-existing retinopathy [1]. Tell your doctor if you have retinopathy, and report any sudden change in vision. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, in type 1 diabetes, and in pregnancy.
Using Ozempic
Ozempic is supplied in a pre-filled pen and injected under the skin (subcutaneously) once a week, on the same day each week, into the abdomen or the thigh, or the upper arm if someone else is administering it [5]. It can be taken with or without food, and at any time of day. Each pen covers four weekly doses [3]. Rotate the site every week rather than injecting the same spot twice in a row.
The practical rules your Kare Team will walk you through on your first injection:
Where to inject: abdomen or thigh (upper arm if administered by someone else). Divide the area into four sections and use a different one each week, keeping each injection at least a finger-width from the last and 5 cm from the belly button.
Your prescribing doctor and Kare Team will demonstrate the injection technique before your first dose. If you also take insulin, never mix the two in one injection or use the same site at the same time. Never change your dose, timing or injection routine without speaking to your doctor first.
Ozempic is never started at a treatment dose. The standard schedule begins at 0.25 mg once weekly for four weeks, moves to 0.5 mg, and then, only where further control is needed, to 1 mg [5]. Ozempic is sold in India in these three pen strengths [3]. This is the typical plan; yours may look different, and your doctor may hold you at a lower dose if it is working.
The initiation dose: it lets your body adjust and is not intended to control blood sugar on its own.
The first therapeutic dose. Many people stay here if their HbA1c reaches target.
The highest strength Ozempic supplies in India, used where further control is required. This is the dose studied in FLOW.
Ozempic launched in India in December 2025 at ₹8,800 a month for the 0.25 mg starting dose, ₹10,170 for 0.5 mg and ₹11,175 for 1 mg [3]. Novo Nordisk then cut prices by roughly 36% in April 2026, ahead of generic competition [4], bringing the starting dose to around ₹5,660. Each pen covers four weekly doses.
| Strength (weekly) | Indicative monthly cost | Notes |
|---|---|---|
| 0.25 mgStarting dose · one pen, four weeks | from ~₹5,660 | Launched at ₹8,800 in December 2025 [3], reduced in April 2026 [4]. |
| 0.5 mgFirst therapeutic dose | see note | Launched at ₹10,170 [3]. Post-reduction figures vary between pharmacies; confirm the current MRP locally. |
| 1 mgHighest strength in India | see note | Launched at ₹11,175 [3]. Post-reduction figures vary between pharmacies; confirm the current MRP locally. |
| April 2026 reductionWhat changed | about 36% lower | Novo Nordisk cut Ozempic prices by roughly 36% and Wegovy by 48% ahead of generic competition [4]. |
| Indian generic semaglutideSame molecule, for comparison | from ~₹1,300–2,200 | DCGI-approved products from Sun Pharma, Eris, Alkem and Zydus. See our generics page. |
The December 2025 launch prices are as reported by Reuters [3] and the April 2026 reduction as reported in the Indian business press [4]. Post-reduction figures for the 0.5 mg and 1 mg pens differ between pharmacy listings, so we have not quoted a single number for them: check the current MRP with your pharmacy. Ozempic is a Schedule H medicine: your dose is decided by your doctor based on your HbA1c, your response and your tolerance, never by price, and dispensing requires a valid prescription. Start with a ₹599 doctor consultation to find out whether treatment is right for you at all.
Comparisons
Four questions patients ask us now that the same molecule is sold in India under more than twenty names.
Information verified by
Same molecule, same manufacturer, different licence and dose range. Ozempic is approved for type 2 diabetes and supplied at 0.25 mg, 0.5 mg and 1 mg. Wegovy is approved for chronic weight management and titrates up to 2.4 mg.
People do lose weight on Ozempic, because semaglutide reduces appetite whatever the label says. But in India it is licensed for diabetes, and prescribing it purely for weight loss is off-label. Read our Wegovy page.
Essentially the brand name and who sells it. Extensior is a second brand of Ozempic: the same original semaglutide, manufactured by Novo Nordisk, commercialised in India by Abbott.
The reason two brands exist is commercial reach. Abbott has a deep distribution network across Indian pharmacies and physicians, so the second brand widens availability. Extensior has generally been listed below Ozempic. Read our Extensior page.
Since the Indian semaglutide patent expired on 20 March 2026, generics from Sun Pharma, Eris, Alkem, Zydus and others have brought the same molecule to roughly ₹1,300 to ₹2,200 a month, against Ozempic's post-reduction pricing from about ₹5,660.
What you pay the difference for is the innovator's own manufacturing and the evidence package attached to it, including the SUSTAIN-6 and FLOW outcome trials on this page. What the generics offer is the same molecule at a fraction of the cost, which matters over a treatment measured in years.
There is no universally correct answer. Cost is one of the biggest reasons people stop treatment early, and a medicine you cannot sustain is not the better medicine.
Switching between semaglutide products at the same strength is usually straightforward because the molecule is identical, and it is normally done at an equivalent dose. It should still be a decision your doctor makes and documents, because device technique differs between brands and formats.
Switching down from a higher-strength formulation needs more planning: if you are on 1.7 mg or 2.4 mg, Ozempic's top strength in India is 1 mg, and that change has consequences for both appetite and glycaemic control. Speak to our Kare team before switching anything.
In India, semaglutide is prescribed by specialist doctors: internal medicine physicians and endocrinologists. It is a Schedule H medicine, and a pharmacy can dispense it solely against a valid prescription from a registered medical practitioner.
Specialists in adult medicine (MD, Internal Medicine), including the Karespot doctors who assess and prescribe for every patient on this programme.
Hormone and metabolism super-specialists (DM, Endocrinology), typically involved in complex diabetes or endocrine cases.
Treatment should never be started or changed on someone else's prescription or advice, because the dose interacts with the rest of your regimen and can cause hypoglycaemia alongside insulin or a sulfonylurea. No gym, wellness clinic or online seller can legitimately supply Ozempic without a prescription. Every Karespot prescription is written by an NMC-registered Internal Medicine doctor after a full assessment. Meet our medical team.
Your doctors
Every Karespot patient is seen by an NMC-registered doctor with specific experience in metabolic medicine, listed with their State Medical Council. Your doctor stays involved from your first consultation to the end of your programme.
Use the arrows, swipe or scroll to meet all 3 prescribers
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Professor of Medicine with deep clinical experience in diabetes and metabolic medicine. He treats type 2 diabetes, insulin resistance and obesity-related metabolic disorders through personalised, evidence-based plans.
Registration: Uttarakhand Medical Council Registered Practitioner: 3461
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Internal medicine physician specialising in metabolic health, weight management, diabetes and lifestyle medicine. He treats root causes (insulin resistance, hormonal imbalance and inflammation) rather than symptoms alone.
Registration: Uttarakhand Medical Council Registered Practitioner: 10178
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Internal medicine physician focused on hormonal and metabolic health. She has helped hundreds of patients manage PMOS (PCOS), thyroid dysfunction and insulin resistance with an empathy-led, evidence-based approach.
Registration: Uttarakhand Medical Council Registered Practitioner: 32876
Speak to a Karespot doctor today
Book in two minutes. A straight answer on eligibility on the same call, including a no, where treatment isn't right for you.
Book your consultation (₹599)Using Ozempic · FAQ
Information verified by
Yes. Ozempic is a Schedule H, prescription-only medicine and can only be dispensed against a valid prescription from a licensed medical doctor.
At Karespot, every patient is assessed by an NMC-registered doctor (MBBS, MD Internal Medicine) before any prescription is issued. If you are not clinically suitable, we will tell you, and refund you.
No. In India Ozempic is approved for type 2 diabetes as an adjunct to diet and exercise. The semaglutide product licensed for chronic weight management is Wegovy, which titrates to a higher 2.4 mg dose.
Weight reduction is a genuine and well-documented effect of semaglutide at any dose, and many people on Ozempic experience it. But if weight is your primary reason for seeking treatment, that is a conversation to have openly with your doctor so the right product is chosen.
Ozempic received CDSCO approval in September 2025 and was launched in India by Novo Nordisk on 12 December 2025, in pen format at 0.25 mg, 0.5 mg and 1 mg [3].
It arrived shortly before the Indian semaglutide patent expired on 20 March 2026, which is why the market changed so quickly through 2026 and why prices were cut in April.
Semaglutide has a half-life of about one week. After your final dose it can remain in the body for roughly five to seven weeks, with full clearance taking around eight to ten weeks depending on individual factors such as kidney function and general health. Its effects on appetite and blood sugar fade gradually rather than stopping abruptly.
Ozempic should be kept in the fridge at 2°C to 8°C. It must not be frozen or exposed to direct light. Storage rules once a pen has been started differ from unopened storage, so follow the instructions in your pack insert, and speak to your Kare Team before travelling rather than improvising the cold chain.
Take your injection on the same day each week to keep levels steady. If you forget a dose:
Monitor your blood sugar more closely around a missed dose, and contact your doctor if readings are unusual.
Effects fade as the medicine clears, and both appetite and blood sugar typically drift back toward where they were. We would rather tell you that honestly upfront.
Type 2 diabetes is a chronic, progressive condition, and semaglutide works while you take it. This is why Karespot pairs medication with dietician coaching, psychologist support and strength-based activity: what you build alongside treatment is what remains if the medicine ever stops.
Still have a question?
Speak to a Karespot doctor and get a clear answer about whether Ozempic is right for you.
Check your eligibilityThe medical information on this page is written and verified by the Karespot clinical content team. It provides general information and is not a substitute for a consultation. Eligibility and treatment decisions are always made by your doctor. Meet our medical team.
Karespot does not sell Ozempic from this page. If a doctor finds semaglutide clinically appropriate for you, it is prescribed and dispensed through a licensed partner pharmacy inside a supervised programme, with dietician, psychologist and coaching support around it.
Treatment is recommended only where clinically appropriate, and every cost is shown transparently before you commit.
Evidence
Every clinical claim and statistic on this page is traceable to one of the sources below (the numbered markers [1]–[5] through the page point here) and each reference links on to the original. Clinical statistics are reported as published. Pricing figures come from news reporting rather than clinical evidence, and are labelled as indicative in the pricing section.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 2016;375:1834–1844.
Source for the cardiovascular outcome figure and for the diabetic retinopathy safety signal, in adults with type 2 diabetes at high cardiovascular risk.
Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine, 2024;391:109–121.
Source for the kidney outcome figures on semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease.
Reuters. Ozempic launches in India with Novo Nordisk pricing low end at $24 a week. 12 December 2025.
Source for the India launch date, the pen format and the 0.25 mg, 0.5 mg and 1 mg strengths, and for the launch prices of ₹8,800, ₹10,170 and ₹11,175 per month.
Business Standard. Emcure slashes obesity drug Poviztra price by up to 55% amid competition. 2 April 2026.
Source for the April 2026 Novo Nordisk price reductions of approximately 36% on Ozempic and 48% on Wegovy.
Novo Nordisk. Semaglutide injection: prescribing and product information.
Manufacturer of Ozempic; source for administration, injection technique, storage, the standard titration schedule, and the side-effect rates reported at these doses.
This page is for information only and is not a substitute for a medical consultation. Ozempic is approved in India as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Treatment is recommended only where it is clinically appropriate for you, following an assessment by a registered medical practitioner. Any prescription-only treatment is provided solely under a valid prescription and active medical supervision, and all products are supplied in compliance with the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Karespot is not affiliated with Novo Nordisk and does not endorse any particular manufacturer or brand; product selection is a clinical decision made by your doctor. Individual results vary. Prices shown are indicative published figures at the time of review and are subject to change.
Ask us anything before you decide. A real person from the Karespot team will answer, not a bot.
We usually reply within a few hours
